A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
Clinical trial NCT06307431 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06307431
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-10
- Primary completion
- 2028-01-08
- Enrollment
- 272
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.